These findings align with a substudy of the APACE trial (Advantageous Predictors of Acute Coronary Syndrome Evaluation), which reported comparable discriminatory performance for cMyBP-C (AUC: 0.924) and hs-cTnT (AUC: 0.927) in detecting myocardial infarction, surpassing conventional troponins such as s-cTnI (AUC: 0.909) [27]. This evidence concerns the gene TNNT2 and acute coronary syndrome.